Bristol-Myers Squibb (BMY) vs Takeda Pharmaceutical (TAK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bristol-Myers Squibb (BMY) has outperformed Takeda Pharmaceutical (TAK) over the past year, gaining 33.8% versus a gain of 29.4%. Over five years, TAK leads with a +31.3% price change compared with +2.1% for BMY. Bristol-Myers Squibb is the larger company by market cap ($121.70 billion vs $59.16 billion), about 2.1 times the size.
On valuation, Bristol-Myers Squibb trades at a lower forward P/E (9.0x vs 34.9x for Takeda Pharmaceutical). Takeda Pharmaceutical offers the higher dividend yield (1079.91% vs 4.21%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMY | TAK |
|---|---|---|
| Share price | $59.58 | $18.52 |
| Market cap | $121.70B | $59.16B |
| 1-day change | -0.20% | +0.82% |
| YTD return | +10.46% | +18.79% |
| 1-year return | +33.77% | +29.42% |
| 5-year return | +2.09% | +31.35% |
| P/E ratio (TTM) | 13.12 | — |
| Forward P/E | 9.02 | 34.94 |
| EPS (TTM) | $4.54 | $-0.34 |
| Dividend yield | 4.21% | 1079.91% |
| Annual dividend | $2.51 | $200.00 |
| Revenue (latest FY) | $48.19B | — |
| Revenue growth (YoY) | -0.22% | — |
| Net income (latest FY) | $7.05B | — |
| Gross margin | 71.08% | — |
| Net margin | 14.64% | — |
| 52-week high | $68.64 | $19.10 |
| 52-week low | $42.52 | $12.99 |
| Distance from 52-week high | -13.20% | -3.04% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +11.06% | +18.57% |
| Average volume | 11.30M | 3.04M |
| Shares outstanding | 2.04B | 3.19B |
| Employees | 32,500 | 47,029 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bristol-Myers Squibb is about 2.1 times larger than Takeda Pharmaceutical by market value ($121.70B vs $59.16B).
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (1079.91% vs 4.21%).
About Bristol-Myers Squibb
BMY stock →Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 32,500 employees
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
BMY vs TAK FAQ
Which is bigger, Bristol-Myers Squibb or Takeda Pharmaceutical?
Bristol-Myers Squibb (BMY) is larger, with a market capitalization of $121.70B compared with $59.16B for Takeda Pharmaceutical (TAK).
Which stock has performed better over the past year, BMY or TAK?
BMY returned +33.77% over the past 12 months, compared with +29.42% for TAK (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Bristol-Myers Squibb or Takeda Pharmaceutical?
Takeda Pharmaceutical has the higher yield at 1079.91%, compared with 4.21% for Bristol-Myers Squibb.
Are Bristol-Myers Squibb and Takeda Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.